))
Effective August 13, 2024, AMDA On-The-Go and all affiliate podcasts will now go by PALTtalk. Explore the field of post-acute and long-term care, with expert interviews, journal article reviews, innovations news, and more. Statements made by guests on this podcast are their own opinions and are not necessarily the positions of the assocation. Speakers’ appearance on the program does not imply an endorsement of them, their views, or any entity they represent.
…
continue reading
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
…
continue reading
Pertussis: EXPOSED is developed and funded by Sanofi, and these podcasts are intended for a healthcare professional audience. Pertussis is generally considered to be an infection of childhood – but are adults at risk too? Listen to the “Pertussis: EXPOSED ” podcast series, where world-renowned experts are exploring the global health concern of pertussis infection across all age groups. In the first two episodes, experts will delve into the unanswered questions surrounding pertussis infection ...
…
continue reading
1
Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia ...
18:59
In this week's episode, we'll learn about the role of a platelet-specific glycoprotein receptor in abdominal aortic aneurysm formation, the influence of TP53 mutations on outcomes for patients with 5q-deleted myelodysplastic syndrome, and a rational combination treatment intended to produce more durable responses in patients with refractory B-cell …
…
continue reading
Episode: October 2024 Host: Alex Bardakh, MPP, CAE Guest: Timothy Holahan, DO, CMD In This Episode: In this episode, Alex Bardakh, MPP, CAE, PALTmed's Senior Director of Advocacy and Strategic Partnerships, and Dr. Timothy Holahan, DO, CMD, Chair of the Public Policy Steering Committee, discuss how PALTC providers can manage work-life balance while…
…
continue reading
1
PALTtalk with Caring | October Issue with Special Guest Melissa McClean on a Geriatric Workforce Enhancement Program
34:13
Episode: October Issue with Special Guest Melissa McClean on a Geriatric Workforce Enhancement Program Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Elizabeth Galik, PhD, CRNP (editor-in-chief); Melissa McClean, MSN, CRNP, ANP-BC, ACHPN In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD,…
…
continue reading
1
Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS
21:48
In this week's episode we'll learn about refining risk stratification in T-cell acute lymphoblastic leukemia, or ALL. After that, we'll discuss a novel gene therapy approach in severe alpha-thalassemia. Investigators describe an innovative mouse model and an effective gene therapy approach, renewing prospects for the development of novel strategies…
…
continue reading
Episode: September 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Joan Carpenter, PhD, CRNP, ACHPN, FPCN; Bridget Morse-Karzen, MPH; Paul Katz, MD, CMD (co-editor-in-chief) In This Episode: In this episode, host Karl Steinberg, MD, CMD, and co-editor-in-chief Paul Katz, MD, CMD, discuss three articles from the September issue. First, they talk …
…
continue reading
1
A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT
18:30
In this week's episode we’ll discuss a novel tripartite fusion drives treatment resistance in acute promyelocytic leukemia. In some patients with atypical APL, these novel retinoic acid receptor gene fusions result in truncation of the ligand binding domain of the retinoic acid receptor protein, resulting in non-responsiveness to treatment with all…
…
continue reading
1
Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis
23:17
In this week's episode we’ll discuss the safety and efficacy of pirtobrutinib with or without rituximab in relapsed/refractory CLL; learn more about erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine; and discuss how targeting PKC alpha alleviates iron overload in diabetes and hemochromatosis through …
…
continue reading
1
Transplant outcomes in pediatric Fanconi anemia; hepatic Foxo1 regulates iron homeostasis; clinical networks improve APL outcomes in Latin America
18:42
In this week's episode we'll discuss outcomes following hematopoietic stem cell transplantation in pediatric patients with Fanconi anemia. Then, we'll learn about how new research shows that the transcription factor Foxo1, commonly associated with glucose metabolism, regulates hepcidin expression and systemic iron homeostasis. Finally, in Latin Ame…
…
continue reading
1
CD8+ T-cell differentiation and treatment response in AML; ATM germline pathogenic variants affect cancer outcomes in ataxia-telangiectasia; efficacy of a selective menin-KMT2A inhibitor in KMT2A- and ...
22:42
In this week's episode we’ll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective m…
…
continue reading
1
PALTtalk Special Edition: Pain Management for Patients with Substance Use Disorder | A Collaboration with the Center of Excellence for Behavioral Health in Nursing Facilities
39:51
Episode: Pain Management for Patients with Substance Use Disorder | A Collaboration with the Center of Excellence for Behavioral Health in Nursing Facilities Host: Diane Sanders-Cepeda, DO, CMD Guest(s): Jennifer Azen, MD; Barbara Resnick, PhD, RN, CRNP, FAAN, FAANP In this Episode: In this episode, host Diane Sanders-Cepeda, DO, CMD, and special g…
…
continue reading
1
TCR-T cells for post-HCT leukemia recurrence; platelets are the predominant source of procoagulant membranes in hemostasis; BR + R maintenance for MCL
18:10
In this week's episode we'll discuss HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Next, we'll learn about how 4D intravital imaging in mice reveals the key role of platelets as a source of procoagulant membranes in hemostasis. Finally, we'll hear about modifications to a common i…
…
continue reading
1
PALTtalk Special Edition: Navigating Conversations and the Latest Science on COVID-19 Vaccine (Part 2 of 2)
27:57
Episode: Navigating Conversations and the Latest Science on COVID-19 Vaccine (Part 2 of 2) Host: Elizabeth Sobczyk, MSW, MPH Guest(s): Leslie Eber, MD, CMD In This Episode: In Episode 2 of our two-part series, host Elizabeth Sobczyk, MSW, MPH, and special guest Leslie Eber, MD, CMD, share practical strategies for clinicians to enhance conversations…
…
continue reading
1
Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors
0:59
In this week's episode we’ll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors. Featu…
…
continue reading
Introduced by Associate Editor Dr. Thomas Ortel, this bonus episode discusses the Review Series on Factor XI, published in volume 143 issue 15 of Blood Journal. Dr. Ortel is joined by contributing authors Owen McCarty, PhD, Gili Kenet, MD, and David Gailani, MD. Review Series Articles: Introduction to a review series on factor XI Biology of factor …
…
continue reading
1
PALTtalk Special Edition: The Practical Two-Part Series | Navigating Access and Billing Challenges for COVID-19 Vaccine (Part 1 of 2)
30:04
Episode: The Practical Two-Part Series | Navigating Access and Billing Challenges for COVID-19 Vaccine (Part 1 of 2) Host: Elizabeth Sobczyk, MSW, MPH Guest(s): Swati Gaur, MD, CMD In This Episode: Join host Elizabeth Sobczyk, MSW, MPH, and special guest Swati Gaur, MD, CMD, as they explore the challenges faced by staff in accessing the COVID-19 va…
…
continue reading
Episode: Getting Started in State Advocacy Host: Carl J. "Christian" Bergman, MD, CMD, FACP Guest(s): Daniel Haimowitz, MD, CMD, from Pennsylvania PALTtalk with Dr. Christian Bergman focuses on state-based grassroots advocacy and policy stories. It offers an in-depth conversation with PALTmed members who are active in their respective states and tr…
…
continue reading
Episode: August 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Dana Mukamel, PhD; Barbara Resnick, PhD, CRNP (co-editor-in-chief) In This Episode: In this episode, host Karl Steinberg, MD, CMD, and co-editor-in-chief Barbara Resnick, PhD, CRNP, will talk with Dana Mukamel, PhD, about her work entitled, The Relationship Between Nursing Home Staf…
…
continue reading
1
Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL
16:56
In this week's episode we'll learn how cytomegalovirus infection early in life depletes preleukemic cells in a mouse model of B-cell acute lymphoblastic leukemia. After that we'll discuss new research, where GVHD targets organoid-forming bile duct stem cells in a TGF-beta-dependent manner. Conversely, a TGF-beta inhibitor protects these stem cells …
…
continue reading
Episode: August/September 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Christopher Laxton; Elizabeth Galik, PhD, CRNP (editor-in-chief) In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD, CRNP, discuss our August/September issue of Caring for the Ages with guest Chris Laxton. This …
…
continue reading
1
Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML
23:31
In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro an…
…
continue reading
Episode: August 2024 Host: Alex Bardakh, MPP, CAE Guest: Timothy Holahan, DO, CMD In this episode, Alex Bardakh, MPP, CAE, PALTmed's Senior Director of Advocacy and Strategic Partnerships, and Timothy Holahan, DO, CMD, Chair of the Public Policy Steering Committee, discuss the latest news from the nation’s capital. Questions? Email Alex at abardakh…
…
continue reading
Episode: Faith and Healing in PALTC Host: Diane Sanders-Cepeda, DO, CMD Guest(s): Sarah McEvoy, NHA, JD; Fatima Naqvi, MD, CMD In This Episode: In this episode, host Diane Sanders-Cepeda, DO, CMD, and special guests Sarah McEvoy, NHA, JD, and Fatima Naqvi, MD, CMD, explore spirituality, connectedness, and the role that PALTC clinicians and leaders …
…
continue reading
1
Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD
16:59
In this week's episode we’ll discuss how immune fitness impacts response to teclistamab in relapsed/refractory multiple myeloma; learn more about a new mechanism of resistance to asciminib conferred by the BCR::ABL1 M244V mutation, and discuss the impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell…
…
continue reading
1
Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity ...
22:53
In this week's episode we’ll discuss the safety and efficacy of decitabine in older patients with AML; learn how heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice, and discuss the outcomes of treatment with HLA-mismatched HSCT with TCRab/CD19 lymphocyte depletion or post-HSCT cyclophosph…
…
continue reading
1
Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism
21:50
In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. Featured Articles: EVIDENCE meta-analysis: evaluating minimal …
…
continue reading
Episode: July 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Tamra Keeney, PT, PhD, DPT, CCS; Daniel Young, PT, DPT, PhD; Paul Katz, MD, CMD (co-editor-in-chief) In This Episode: In this episode, host Karl Steinberg, MD, CMD, and co-editor-in-chief Paul Katz, MD, CMD, will discuss three articles from the July issue. First, they will talk with T…
…
continue reading
1
Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT
23:32
In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Featured Articles:…
…
continue reading
Episode: July 2024 Host: Alex Bardakh, MPP, CAE Guest: Timothy Holahan, DO, CMD In this episode, Alex Bardakh, MPP, CAE, the Society’s Senior Director of Advocacy and Strategic Partnerships, and Timothy Holahan, DO, CMD, Chair of the Public Policy Steering Committee, discuss the latest news from the nation’s capital. Questions? Email Alex at abarda…
…
continue reading
Episode: June/Juy 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Daniel Haimowitz, MD, FACP, CMD; Elizabeth Galik, PhD, CRNP (editor-in-chief) In This Episode: In this episode, host Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD, CRNP, discuss our June/July issue of Caring for the Ages with guest Daniel Haimowitz, MD, FAC…
…
continue reading
1
Clinical impact of CRh in AML; thrombosis features in a real-life PNH cohort; and restriction of SOX11 expression to EBV-negative Burkitt lymphomas
19:58
In this week's episode we'll learn about the clinical benefit of complete remission with partial hematological recovery, or CRh, in patients with Acute Myeloid Leukemia (AML) treated with molecularly targeted drugs. Then we'll hear about a large cohort of patients with PNH were studied to detail PNH-related thrombotic events, unravel determinants o…
…
continue reading
Episode: The Empowering Three-Part Series | Boundaries With Care (Part 3 of 3) Host: Diane Sanders-Cepeda, DO, CMD Guest(s): Aya Caspi In This Episode: In this episode, host Diane Sanders-Cepeda, DO, CMD, and special guest Aya Caspi, discuss boundaries with care, including how to care for ourselves without dropping others and how this will enhance …
…
continue reading
1
Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome
23:25
In this week's episode we’ll discuss the mutational and transcriptional landscape of pediatric BCP lymphoblastic leukemia; learn more about the role of platelet-derived TGF-β1 in immune thrombocytopenia; and discuss the findings from a phase 3 trial of mavorixafor in WHIM syndrome. Featured Articles: Mutational and transcriptional landscape of pedi…
…
continue reading
1
AMDA On-The-Go | The Empowering Three-Part Series | Speaking and Listening in Ways That Matter (Part 2 of 3)
36:31
Episode: The Empowering Three-Part Series | Speaking and Listening in Ways That Matter (Part 2 of 3) Host: Diane Sanders-Cepeda, DO, CMD Guest(s): Aya Caspi In This Episode: In this episode, host Diane Sanders-Cepeda, DO, CMD, and special guest Aya Caspi, discuss how to speak and listen in a way that lets others know they matter without having to a…
…
continue reading
Introduced by Associate Editor Robert Zeiser, this Review Series focuses on the problem of immune escape by acute myeloid leukemia (AML). The series opens with a review of how AML escapes T-cell–driven elimination and then focuses on how p53 function impinges on AML recognition by immune cells. The series finishes with a summary of new approaches t…
…
continue reading
1
GM-CSF coordinates shelter in the cytokine storm; Interleukin-1 as a therapeutic target in TTP; CAR T-cell outcomes across race and ethnicity in LBCL
19:57
In this week's episode we'll discuss new insights on the role of GM-CSF in establishing immune memory. The authors propose that the coordination of opposing immune memory programs, driven by GM-CSF, may be essential to efficient, yet controlled, innate immune responses. After that: Interleukin-1 inhibition in TTP. Researchers explore the potential …
…
continue reading
Episode: June 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Tess Jones, PhD, LMSW; Barbara Resnick, PhD, CRNP (co-editor-in-chief) In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and co-editor-in-chief Dr. Barb Resnick, PhD, CRNP, will talk with Tessa Jones, PhD, LMSW, about her work entitled, Race and Ethnicity Are Related…
…
continue reading
1
Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease
23:39
In this week's episode we’ll discuss the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies, learn how peak ADAMTS13 activity can be used to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura, and discuss the findings from a phase …
…
continue reading
Episode: The Empowering Three-Part Series | Building Trust (Part 1 of 3) Host: Diane Sanders-Cepeda, DO, CMD Guest(s): Aya Caspi In This Episode: In this episode, host Diane Sanders-Cepeda, DO, CMD, and special guest Aya Caspi, discuss what to do and say to show care and restore trust when our choices of words and actions have a negative impact on …
…
continue reading
1
A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy
19:16
In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell tran…
…
continue reading
1
Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma ...
23:05
In this week's episode we’ll discuss the safety and efficacy of nilotinib with or without cytarabine in Philadelphia-positive acute lymphoblastic leukemia; learn more about thrombosis risk in double heterozygous carriers of Factor V Leiden and prothrombin G20210A and discuss the utility of circulating cell-free tumor DNA in prognostic prediction in…
…
continue reading
Episode: May 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Geoffrey Gusoff, MD, MBA, MS; Stina Ek, PhD; Paul Katz, MD, CMD (co-editor-in-chief) In This Episode: In this episode, host Karl Steinberg, MD, CMD, and co-editor-in-chief Paul Katz, MD, CMD, will discuss three articles from the May issue. First, they will talk with first author Geoffr…
…
continue reading
1
Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML
18:59
In this week's episode we'll learn about fitusiran prophylaxis in patients with hemophilia A or B, with or without inhibitors. Next we'll hear about new findings that heterozygous germline variants in the NBN gene that are linked to increased risk of B-cell acute lymphoblastic leukemia in children. Finally, we'll explore new insights on the histone…
…
continue reading
1
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia
22:26
In this week's episode we’ll discuss the effects of voxelotor on cerebral blood flow in pediatric sickle cell disease, learn more about venous and arterial thrombosis in patients with Vexas syndrome, and discuss differential sensitivity to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia. Featured Articles: The influence of voxe…
…
continue reading
1
Stamping out high-risk myeloma with D-KRd and tandem transplant; plasmin-cleaved VWF in microthrombosis; SCD plasma sensitizes iPSC-derived sensory neurons
19:40
In this week's podcast we'll discuss another step forward in stamping out high-risk myeloma. Then we'll hear about the plasmin-cleaved von Willebrand factor, or VWF, in microthrombosis. Finally we'll hear about new insights into the origins of sickle cell pain. Featured Articles: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem…
…
continue reading
1
AMDA On-The-Go | D2D Edition | Deprescribing of Anticoagulants: The IF, WHEN and HOW, a Discussion with a Cardiologist
35:41
Episode: D2D Edition | Deprescribing of Anticoagulants: The IF, WHEN and HOW, a Discussion with a Cardiologist Host: Sabine von Preyss-Friedman MD, FACP, CMD Guest(s): Nicole Orr, MD; Irene Hamrick MD, CMD In This Episode: In this episode, host Sabine von Preyss-Friedman, MD, FACP, CMD, and special guests Nicole Orr, MD, and Irene Hamrick, MD, CMD,…
…
continue reading
1
Caring On-The-Go | May 2024: Heart Disease and Matters of the Heart, With Special Guest Dr. Nicole Orr
34:25
Episode: May 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Elizabeth Galik, PhD, CRNP (editor-in-chief); Nicole Orr, MD In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD, CRNP, discuss our May issue of Caring for the Ages with guest Nicole Orr, MD. This issue contains and special s…
…
continue reading
1
Allogeneic transplant in first remission for post-induction molecular MRD; circulating HSPCs actively participate in human hematopoiesis; let-7 miRNAs repress HIC2 to regulate BCL11A transcription and ...
21:44
In this week's episode we’ll discuss the utility of MRD in identifying patients with NPM1 AML who benefit from allogeneic transplant in first remission, learn more about the contribution of circulating hematopoietic stem/progenitor cell subsets to human hematopoietic hemostasis, and discuss the role of Let-7 miRNAs in regulation of BCL11A transcrip…
…
continue reading
1
ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins
19:10
In this week's epside we'll learn about ADAMTS recovery after caplacizumab therapy in patients with immune thrombotic thrombocytopenic purpura. Then, we'll hear about preclinical characterization of sonrotoclax, a potential second-generation BCL2 inhibitor. Finally we'll hear about new insights into the etiology of Castleman disease where researche…
…
continue reading
1
Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction ...
23:49
In this week's episode, we’ll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and …
…
continue reading
1
Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?
19:00
In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients wi…
…
continue reading
